|1.||Soejima, Kazutaka: 1 article (05/2006)|
|2.||Nozaki, Motohiro: 1 article (05/2006)|
|3.||Chen, Xin: 1 article (05/2006)|
|4.||Hori, Keijiro: 1 article (05/2006)|
|5.||Sakurai, Hiroyuki: 1 article (05/2006)|
|6.||Takeuchi, Masaki: 1 article (05/2006)|
|7.||Hu, C X: 1 article (07/2001)|
|8.||Zhang, Y: 1 article (07/2001)|
|9.||Zhu, X D: 1 article (07/2001)|
|10.||Schopf, E: 1 article (11/2000)|
11/01/1992 - "To assess the efficacy of topically applied CT-102 APST for treating diabetic neurotrophic foot ulcers. "
11/01/1992 - "Thirteen patients entered a randomized, double-blind trial of topically applied CT-102 APST vs. placebo (normal saline) gauze dressings for the treatment of nonhealing diabetic neurotrophic foot ulcers. "
12/01/1999 - "In a placebo controlled study we tried topical application of autologous PDWHF (platelet derived wound healing factors), to achieve ulcer healing and improve the microangiopathy surrounding of the ulcer area, as there are decreased number of skin capillaries and reduction in cutaneous vascular reserve. "
09/01/1986 - "This study utilized autologous platelet-derived wound healing factors (PDWHF) to treat 49 patients with chronic nonhealing cutaneous ulcers. "
12/01/1999 - "In den PDWHF group an ulcer area of 26.9 cm2 was measured at the beginning, of 26.2 cm2 at the end; in the placebo group, 34.7 cm2 and 35.5 cm2. "
01/01/1995 - "In this prospective study the stimulating effect of autologous PDWHF on epithelialization of small ulcers (group A, < 5000 mm2) and granulation of large ulcers before mesh grafting (> 5000 mm2) will be demonstrated. "
01/01/1991 - "Preliminary results suggest that PDWHF improves the healing of diabetic ulcers of the lower extremity."
|3.||Wounds and Injuries (Trauma)
05/01/2006 - "The present study revealed that treatment with PDWHF, combined with cultured endothelial cells and fibroblasts, accelerated wound angiogenesis. "
05/01/2006 - "To enhance the wound angiogenesis, cultured endothelial cells, fibroblasts and PDWHF (platelet derived wound healing factor) were employed. "
07/01/2001 - "PDWHF (100 micrograms/wound) was topically applied to one side of the diabetic wounds (group B) on the operation day and then once a day in the next successive 6 days. "
07/01/1998 - "This experiment was designed to observe the proliferative effects of platelet derived wound healing factor (PDWHF) of different concentrations on fibroblasts from rat wounds and on epithelial from human wounds. "
10/01/1993 - "Treatment of wounds with procuren."
|4.||Spinal Cord Injuries (Spinal Cord Injury)
01/01/1992 - "The effect of growth factor formula (platelet derived wound healing formula) in experimental spinal cord injuries."
07/01/1996 - "Complete spinal cord transection was performed at T12 in rats and the treatment of the spinal cord injury was achieved by filling the dead space with type 1 collagen gel impregnated with PDWHF, or with 2.5S-NGF. "
01/01/1993 - "PDWHF seems to play a role in the healing processes of spinal cord injury and may have important interactions with other growth factors and in particular neurogenic growth factor."
01/01/1992 - "The main purpose of this study was to investigate the usefulness of platelet derived wound healing formula (PDWHF) in the treatment of experimentally induced spinal cord injuries in cats. "
07/01/1996 - "The main purpose of this study is to investigate the effect of platelet derived wound healing formula (PDWHF) and nerve growth factor (NGF) in the treatment of experimental spinal cord injury. "
|5.||Wound Infection (Wound Infections)
|1.||CT-102 activated platelet supernatant
|2.||Nerve Growth Factor (NGF)
|3.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|5.||Collagen Type I (Type I Collagen)
|6.||RNA-Directed DNA Polymerase (Reverse Transcriptase)